Saturday, September 19, 2026

Corporate Earnings & M&A

2 articles

Serve Robotics Raises 2026 Guidance as Delivery Automation Attracts M&A Activity

Serve Robotics Raises 2026 Guidance as Delivery Automation Attracts M&A Activity

Serve Robotics lifted its 2026 revenue guidance amid growing last-mile delivery adoption, while acquiring Vayu to strengthen its physical AI capabilities. The autonomous delivery sector is drawing acquisition interest as companies race to scale commercial deployments alongside parallel defense robotics growth.

LM Salvado
Fixed Index Annuity Issuers Add Growth-Focused Indices as Market Consolidates

Fixed Index Annuity Issuers Add Growth-Focused Indices as Market Consolidates

North American, one of the largest U.S. fixed index annuity issuers, launched a new growth-focused index option with Annexus to enhance portfolio diversification. The product expansion reflects broader sector trends including dividend increases signaling strong cash flows and strategic acquisitions reshaping the competitive landscape.

ViaNews Editorial Team (Markets)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com